Abstract
Regionally specific neuronal loss is a distinguishing feature of Alzheimer disease (AD). Excitotoxicity is a mechanism commonly invoked to explain this. We review the accumulating evidence for such a hypothesis, particularly the altered expression and pharmacology of glutamate receptors and transporters in pathologically susceptible regions of the AD brain. Loss of neurons would be expected to lead to the retrograde degeneration of their afferents, which should be reflected in a loss of presynaptic markers such as synaptophysin. We discuss the possibility that neurons may be destroyed locally, but that glutamatergic presynaptic terminals may remain, or even re-proliferate. The reduced glutamate uptake site density in AD brain may signify a loss of the transporters on otherwise intact terminals, rather than the loss of glutamatergic afferents. Neuronal death may follow if cells are exposed to excessive amounts of glutamate; the loss of transporters from functioning, but defective, glutamate termin als would mean they could continue to release glutamate to exacerbate excitotoxicity. We discuss experimental methods to quantitate synapses, which are crucial for deciding between the various possibilities.
Keywords: Excitatory Amino Acids, Neurotoxicity, Cerebral Cortex, Glutamate - Receptors, Glutamate - Transporters, Synaptic Terminals, Neurodegenerative Diseases
Current Alzheimer Research
Title: The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease
Volume: 1 Issue: 1
Author(s): Rudi K. Tannenberg, Heather L. Scott, Robert I. Westphalen and Peter R. Dodd
Affiliation:
Keywords: Excitatory Amino Acids, Neurotoxicity, Cerebral Cortex, Glutamate - Receptors, Glutamate - Transporters, Synaptic Terminals, Neurodegenerative Diseases
Abstract: Regionally specific neuronal loss is a distinguishing feature of Alzheimer disease (AD). Excitotoxicity is a mechanism commonly invoked to explain this. We review the accumulating evidence for such a hypothesis, particularly the altered expression and pharmacology of glutamate receptors and transporters in pathologically susceptible regions of the AD brain. Loss of neurons would be expected to lead to the retrograde degeneration of their afferents, which should be reflected in a loss of presynaptic markers such as synaptophysin. We discuss the possibility that neurons may be destroyed locally, but that glutamatergic presynaptic terminals may remain, or even re-proliferate. The reduced glutamate uptake site density in AD brain may signify a loss of the transporters on otherwise intact terminals, rather than the loss of glutamatergic afferents. Neuronal death may follow if cells are exposed to excessive amounts of glutamate; the loss of transporters from functioning, but defective, glutamate termin als would mean they could continue to release glutamate to exacerbate excitotoxicity. We discuss experimental methods to quantitate synapses, which are crucial for deciding between the various possibilities.
Export Options
About this article
Cite this article as:
Tannenberg K. Rudi, Scott L. Heather, Westphalen I. Robert and Dodd R. Peter, The Identification and Characterization of Excitotoxic Nerve-endings in Alzheimer Disease, Current Alzheimer Research 2004; 1 (1) . https://dx.doi.org/10.2174/1567205043480591
DOI https://dx.doi.org/10.2174/1567205043480591 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry Coumarin Compounds in Medicinal Chemistry: Some Important Examples from the Last Years
Current Topics in Medicinal Chemistry Conference Report: The Myriad Pathways of Neurodegeneration Discussed at NEUROCON 2015
Current Aging Science Chinese Herbs and Herbal Extracts for Neuroprotection of Dopaminergic Neurons and Potential Therapeutic Treatment of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Innovative Approaches for the Management of Pediatric Malignancies)
Current Medicinal Chemistry Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry Modulation of k-Ras Signaling by Natural Products
Current Medicinal Chemistry Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging
Mini-Reviews in Medicinal Chemistry The Mitochondriotropic Effects of L-carnitine and its Esters in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets Strategies Targeting Soluble β-Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research Cross Talk between the Cardiovascular and Nervous Systems:Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development
Current Pharmaceutical Design From Protein to Peptides: a Spectrum of Non-Hydrolytic Functions of Acetylcholinesterase
Protein & Peptide Letters Cellomics as Integrative Omics for Cancer
Current Proteomics Exploiting Microwave-Assisted Organic Synthesis (MAOS) for Accessing Bioactive Scaffolds
Current Organic Chemistry CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro
Current Alzheimer Research NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Neurokinin-1 Receptor Antagonists as Anticancer Drugs
Letters in Drug Design & Discovery